Imunexus Therapeutics Ltd is an Australian biotechnology company developing next-generation multispecific biologic medicines for serious diseases.
Our lead program, IMX39, is a patented multispecific biologic candidate for multiple sclerosis developed using the company’s imunexin™ platform.
IMX39 is designed to address key biological drivers of multiple sclerosis rather than simply suppress inflammation. In preclinical studies the program demonstrated encouraging results, including reduced disease symptoms and preservation of neurological function.
The global market for multiple sclerosis therapies exceeds US$27 billion, highlighting the need for improved treatment options.
The imunexin™ platform enables conventional biologic drugs to be enhanced with small human protein modules that provide additional therapeutic functions. This approach supports the creation of new intellectual property while potentially improving the performance of existing biologics.
Beyond IMX39, Imunexus is advancing a pipeline spanning oncology, rare diseases and regenerative medicine, with collaborations established with Mesoblast Ltd and The Baker Heart & Diabetes Institute.
